Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report

Key Takeaways

• Air‑cargo capacity down 22% since conflict began.
• API shipments from Jordan face 48%‑73% regional dependence.
• Strait of Hormuz risk raises insurance and freight costs.
• Potential Bab al‑Mandeb closure could force Cape reroutes.
• Shortages may push U.S. pharma reshoring initiatives.

Pulse Analysis

The geopolitical flare‑up between the United States and Iran has exposed a fragile underbelly in global pharmaceutical logistics. While the Strait of Hormuz has long been a conduit for oil, it also underpins the movement of petrochemical‑derived starting materials essential to API production. Simultaneously, the shutdown of Gulf air hubs—critical nodes for temperature‑sensitive biologics—has trimmed air‑cargo capacity by roughly a fifth, inflating freight rates and insurance premiums. These constraints reverberate through a supply chain already stretched thin by just‑in‑time inventory models, especially for generic manufacturers operating on razor‑thin margins.

Beyond the immediate transport bottlenecks, the conflict threatens the continuity of specific drug ingredients. Nearly half of the world’s amoxicillin oral suspension and a similar share of doxycycline capsules originate from Jordan, while key APIs for flumazenil and etomidate are produced in Israel and Jordan. Any prolonged delay in these corridors can cascade into production slowdowns, prompting manufacturers to scramble for alternative sources at higher costs. The resulting price pressure is likely to be passed on to patients, amplifying concerns about affordability and access in markets heavily reliant on imported medicines.

In response, industry leaders and policymakers are intensifying discussions around reshoring and nearshoring pharmaceutical manufacturing. Recent U.S. initiatives—ranging from tax incentives to the Most Favored Nation pricing framework—aim to reduce dependence on geopolitically volatile regions. While building domestic capacity requires substantial capital and time, the current risk landscape may accelerate investment cycles, encouraging a more geographically diversified supply chain. Stakeholders that proactively adapt to these disruptions will better safeguard drug availability and mitigate future volatility.